These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

462 related items for PubMed ID: 29325609

  • 1. The CAG-polyglutamine repeat diseases: a clinical, molecular, genetic, and pathophysiologic nosology.
    Stoyas CA, La Spada AR.
    Handb Clin Neurol; 2018; 147():143-170. PubMed ID: 29325609
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Molecular genetics and biomarkers of polyglutamine diseases.
    Katsuno M, Banno H, Suzuki K, Takeuchi Y, Kawashima M, Tanaka F, Adachi H, Sobue G.
    Curr Mol Med; 2008 May; 8(3):221-34. PubMed ID: 18473821
    [Abstract] [Full Text] [Related]

  • 4. The CAG/polyglutamine tract diseases: gene products and molecular pathogenesis.
    Koshy BT, Zoghbi HY.
    Brain Pathol; 1997 Jul; 7(3):927-42. PubMed ID: 9217976
    [Abstract] [Full Text] [Related]

  • 5. [Molecular biology of polyglutamine diseases].
    Owecki M, Kozubski W.
    Postepy Hig Med Dosw; 2002 Jul; 56(6):779-88. PubMed ID: 12661407
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Correlation of inter-locus polyglutamine toxicity with CAG•CTG triplet repeat expandability and flanking genomic DNA GC content.
    Nestor CE, Monckton DG.
    PLoS One; 2011 Jul; 6(12):e28260. PubMed ID: 22163004
    [Abstract] [Full Text] [Related]

  • 8. [The Role of Mutant RNA in the Pathogenesis of Huntington's Disease and Other Polyglutamine Diseases].
    Bogomazova AN, Eremeev AV, Pozmogova GE, Lagarkova MA.
    Mol Biol (Mosk); 2019 Jul; 53(6):954-967. PubMed ID: 31876275
    [Abstract] [Full Text] [Related]

  • 9. Trinucleotide repeat expansion in neurological disease.
    La Spada AR, Paulson HL, Fischbeck KH.
    Ann Neurol; 1994 Dec; 36(6):814-22. PubMed ID: 7998766
    [Abstract] [Full Text] [Related]

  • 10. [Therapeutic strategies for the polyglutamine diseases].
    Nagai Y, Popiel HA, Fujikake N, Toda T.
    Brain Nerve; 2007 Apr; 59(4):393-404. PubMed ID: 17447526
    [Abstract] [Full Text] [Related]

  • 11. Canadian Association of Neurosciences Review: polyglutamine expansion neurodegenerative diseases.
    Truant R, Raymond LA, Xia J, Pinchev D, Burtnik A, Atwal RS.
    Can J Neurol Sci; 2006 Aug; 33(3):278-91. PubMed ID: 17001815
    [Abstract] [Full Text] [Related]

  • 12. [Triplet repeat disease, with particular emphasis of spinal and bulbar muscular atrophy (SBMA)].
    Sobue G.
    Rinsho Shinkeigaku; 2000 Dec; 40(12):1193-5. PubMed ID: 11464455
    [Abstract] [Full Text] [Related]

  • 13. Polyglutamine pathogenesis: emergence of unifying mechanisms for Huntington's disease and related disorders.
    Ross CA.
    Neuron; 2002 Aug 29; 35(5):819-22. PubMed ID: 12372277
    [Abstract] [Full Text] [Related]

  • 14. Potential therapeutic targets in polyglutamine-mediated diseases.
    Katsuno M, Watanabe H, Yamamoto M, Sobue G.
    Expert Rev Neurother; 2014 Oct 29; 14(10):1215-28. PubMed ID: 25190502
    [Abstract] [Full Text] [Related]

  • 15. The Expanding Clinical Universe of Polyglutamine Disease.
    Huang S, Zhu S, Li XJ, Li S.
    Neuroscientist; 2019 Oct 29; 25(5):512-520. PubMed ID: 30614396
    [Abstract] [Full Text] [Related]

  • 16. [Dynamic mutations in hereditary neurodegenerative disorders].
    Nilssen O.
    Tidsskr Nor Laegeforen; 1999 Aug 30; 119(20):3021-7. PubMed ID: 10504853
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Autophagy and Polyglutamine Disease.
    Ren H, Hao Z, Wang G.
    Adv Exp Med Biol; 2020 Aug 30; 1207():149-161. PubMed ID: 32671744
    [Abstract] [Full Text] [Related]

  • 19. Current understanding on the pathogenesis of polyglutamine diseases.
    He XH, Lin F, Qin ZH.
    Neurosci Bull; 2010 Jun 30; 26(3):247-56. PubMed ID: 20502504
    [Abstract] [Full Text] [Related]

  • 20. Selective suppression of polyglutamine-expanded protein by lipid nanoparticle-delivered siRNA targeting CAG expansions in the mouse CNS.
    Hirunagi T, Sahashi K, Tachikawa K, Leu AI, Nguyen M, Mukthavaram R, Karmali PP, Chivukula P, Tohnai G, Iida M, Onodera K, Ohyama M, Okada Y, Okano H, Katsuno M.
    Mol Ther Nucleic Acids; 2021 Jun 04; 24():1-10. PubMed ID: 33738134
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.